| 13.49 0.33 (2.51%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.19  |
1-year : | 17.16 |
| Resists | First : | 13.86 |
Second : | 14.69 |
| Pivot price | 13.19  |
|||
| Supports | First : | 12.51 | Second : | 10.4 |
| MAs | MA(5) : | 13 |
MA(20) : | 13.18 |
| MA(100) : | 11.3 |
MA(250) : | 9.21 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 35.9 |
D(3) : | 23.5 |
| RSI | RSI(14): 50.5 |
|||
| 52-week | High : | 21.72 | Low : | 5.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ WVE ] has closed below upper band by 29.5%. Bollinger Bands are 68.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.6 - 13.65 | 13.65 - 13.71 |
| Low: | 12.75 - 12.8 | 12.8 - 12.86 |
| Close: | 13.4 - 13.5 | 13.5 - 13.6 |
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Thu, 19 Feb 2026
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026 - Bitget
Wed, 18 Feb 2026
Analysts Confirm Bullish Outlook on Wave Life (WVE) Over Obesity Treatment - Finviz
Wed, 18 Feb 2026
BofA Highlights WVE-007 as Primary Driver For Wave Life Sciences Ltd. (WVE)’s Growth, Projecting Peak Sales Above $11B - Yahoo Finance
Tue, 17 Feb 2026
Wave Life Sciences: WVE-006 Now In Focus, Navigating Opportunity And Risk (NASDAQ:WVE) - Seeking Alpha
Tue, 17 Feb 2026
Wave Life Sciences Ltd. (WVE) Investor Outlook: Analyzing a 163% Potential Upside in Biotechnology - DirectorsTalk Interviews
Mon, 16 Feb 2026
Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 186 (M) |
| Shares Float | 88 (M) |
| Held by Insiders | 13.7 (%) |
| Held by Institutions | 79.8 (%) |
| Shares Short | 15,190 (K) |
| Shares Short P.Month | 14,690 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.77 |
| Profit Margin | -111.7 % |
| Operating Margin | -740.8 % |
| Return on Assets (ttm) | -28.4 % |
| Return on Equity (ttm) | -86.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.36 |
| Sales Per Share | 0.58 |
| EBITDA (p.s.) | -0.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -197 (M) |
| Levered Free Cash Flow | -148 (M) |
| PE Ratio | -20.76 |
| PEG Ratio | 0 |
| Price to Book value | 17.29 |
| Price to Sales | 22.94 |
| Price to Cash Flow | -12.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|